SecBot SecBot
3 ·Filed Nov 10, 2026
AZ

AZR

Azora Therapeutics, Inc. (DE)
NEUTRAL
Impact 2/10
Horizonimmediate Processed7d 9h ago SEC0001213900-26-117772
Actionable Insight • Neutral

These Form 3 filings confirm the appointment of three new insiders but provide no ownership or transaction data. Monitor future Form 4 filings for any share acquisitions or sales by these individuals, which would signal their conviction level.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$3.76
T+0 close · Nov 10, 2026 · via day close
Latest settled
−2.53%
T+5 · $3.67
Vs SPY
−0.20%
α at T+5
Next horizon
T+20
in 22d
  1. T+0 · Nov 10 $3.76entry
  2. T+1 · 6d ago −6.65%α −7.97% · $3.51
  3. T+5 · 11h ago −2.53%α −0.20% · $3.67
  4. T+20 · in 22d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Three new insiders, Paul J. Hastings, Aida Habtezion, and Thomas M. Soloway, filed initial statements of beneficial ownership (Form 3) for Azora Therapeutics, each reporting zero shares beneficially owned. The filings are routine administrative steps for new officers or directors, with no financial data or trading activity disclosed.

Key Facts

  • Paul J. Hastings filed Form 3 on 2026-11-10, reporting 0 shares beneficially owned as of 2026-11-03.
  • Aida Habtezion filed Form 3 on 2026-11-10, reporting 0 shares beneficially owned as of 2026-11-03.
  • Thomas M. Soloway filed Form 3 on 2026-11-10, reporting 0 shares beneficially owned as of 2026-11-03.
  • Each filing included a power of attorney appointing Matthew Gene Davidson and others as attorneys-in-fact for SEC filings.
  • Azora Therapeutics has a market cap of $11M and a normal daily move of 9.3%.

Financial Impact

No financial impact; each insider reported zero beneficial ownership.

Risk Factors

  • No ownership data disclosed; insiders may acquire shares later, creating potential dilution or signaling.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 12 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (AZR), Batch item 10001213900-26-117772
Document: 0001213900-26-117772-index-headers.html0001213900-26-117771
Document: 0001213900-26-117772-index.html0001213900-26-117773
Document: 0001213900-26-117772.txt0001213900-26-117772
3 Filing (AZR), Batch item 50001213900-26-117771
Document: 0001213900-26-117771-index-headers.html0001213900-26-117772
Document: 0001213900-26-117771-index.html0001213900-26-117772
Document: 0001213900-26-117771.txt0001213900-26-117772
3 Filing (AZR), Batch item 90001213900-26-117773
Document: 0001213900-26-117773-index-headers.html0001213900-26-117772
Document: 0001213900-26-117773-index.html0001213900-26-117772
Document: 0001213900-26-117773.txt0001213900-26-117772

Track record

5 reports on AZR

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today S-3 Bearish 6/10 Entry $3.81 Now $3.66 +3.81% settles Nov 24
  2. Nov 12, 20265d ago 8-K Neutral 4/10 Entry $4.09 Now $3.66 −10.39% settles Nov 20
  3. Nov 10, 20267d ago 3 Neutral 2/10 Viewing Entry $3.76 to $3.67 Now $3.66 −2.53% ▼ −2.53% −0.20% vs SPY
  4. Nov 9, 20268d ago 8-K Neutral 4/10 Entry $3.75 to $3.81 Now $3.66 −2.27% ▲ +1.60% +3.29% vs SPY
  5. Nov 3, 202614d ago SC 13G/A Bearish 4/10 Entry $4.15 to $3.76 Now $3.66 +11.69% ▲ +9.40% +8.81% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026